Topical therapy of contaminated wounds of various location and origin; prevention of secondary contamination of wounds in the granulation phase; therapy of burns (II and IIIA degrees); ensuring readiness for the procedure of dermatoplasty of burn wounds; pyodermas caused by streptococci and staphylococci, fungal lesions of the skin and nails (dermatophytosis, onychomycosis), keratomycosis (including pityriasis versicolor), lesions of the skin and mucous membranes by fungi of the genus candida; in case of minor injuries received at home or at work, in order to prevent the development of complications of wound infection.

For topical use in adult patients.

Therapy of wounds and burns. The preparation is distributed directly over the area of damaged skin, previously treated by generally accepted methods. Then a sterile gauze bandage is applied to the damaged treated area. It is possible to apply the ointment first to the dressing material, and then to the wound.

It is possible to fill the cavities of surgically treated purulent wounds or fistulas with ointment-soaked tampons or gauze turunds.

In the inflammatory phase, the ointment is used once a day, in the regeneration phase, the frequency of application is reduced to once every 1-3 days (depends on the condition of the wound). The dose of the preparation is determined by the volume of the lesion and the severity of purulent exudation. The speed of the process of cleaning the wound and restoring the damaged tissue affects the duration of therapy.

Infection of deeply located soft tissues requires the combined use of miramistin with systemic antibiotics, which determines the total duration of therapy.

Application in dermatology. Ointment 1-2 times a day is distributed in a thin layer on the affected skin or on the dressing material with subsequent application to the damaged areas. Therapy should be continued until negative microbiological test results are obtained. In the case of extensive damage to the skin by dermatophytes, it is allowed to use miramistin ointment for 5-6 weeks in combination with griseofulvin (or systemic fungicides). The presence of onychomycosis requires preliminary exfoliation of the affected nail plates.

Hypersensitivity to miramistin or other components of the preparation.

Occasionally, preparation therapy for burns and trophic ulcers may be accompanied by minor smoking. this effect quickly disappears (within 15-20 seconds) involuntarily without the use of painkillers or discontinuation of the preparation.

Hypersensitivity reactions are also likely (among other things rash, itching, hyperemia, dryness, dermatitis, skin maceration). The presence of propylene glycol in the preparation can lead to skin irritation.

Irrigation of the wound surface with a solution with antibacterial properties before applying the ointment increases the effectiveness of the preparation.

In the case of wound contents of a purulent-necrotic nature, it is necessary to increase the amount of ointment used.

Since there is no significant data on the use of the preparation during pregnancy and breastfeeding, it is necessary to consult a doctor before using it in this category of patients.

The preparation is not used in children.

Miramistin ointment does not affect the speed of reaction when driving vehicles or working with machinery.

Simultaneous topical use of surfactants of the anionic class with miramistin reduces its activity.

Miramistin helps to increase the sensitivity of microorganisms to antibiotics when it is used simultaneously with preparations of this group.

No cases of overdose were found. however, in case of distribution of miramistin ointment over a large area of skin, penetration of active ingredients into the blood is possible. however, their quantity does not lead to toxic effects.

The systemic effect of miramistin is characteristic of surfactants of the cationoactive class, an increase in the bleeding period is possible.

Therapeutic measures in case of overdose include cancellation of treatment or reduction of the dose of the preparation. Calcium preparations are used per os, Vikasol.

At a temperature ≤25 °C in the original packaging.